In show­down with Roche, Re­gen­eron gears up for po­ten­tial Eylea ex­pan­sion amid Covid de­cline

Re­gen­eron faced a sub­stan­tial slump in over­all rev­enue last year, but the fo­cus still re­mains on some of its biggest block­busters.

The phar­ma with sev­er­al high-pro­file part­ner­ships — Sanofi and Bay­er among them — said Fri­day that Q4 rev­enue was down 31% for the quar­ter, and down 24% for the en­tire year. How­ev­er, that won’t stop block­buster ex­pan­sion plans.

One of those is Eylea, the Bay­er-part­nered eye dis­ease drug that has been in ma­jor com­pe­ti­tion with Roche’s Vabysmo. While Eylea is cur­rent­ly on­ly ap­proved in a 2 mg dose, the com­pa­ny re­cent­ly filed for ap­proval to give a 8 mg dose, in hopes of mak­ing a longer-last­ing treat­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER